Theravance Biopharma TBPH Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $288.1M+160% | $167.81M+344% | $174.77M+648% | $281.93M+508% | $110.61M+105% | ||
| $106.57M+426% | $147.55M+192% | $154.91M+128% | $56.88M+14.4% | $20.24M-56.1% | ||
| $836K0.0% | $836K0.0% | $836K0.0% | $836K0.0% | $836K0.0% | ||
| $7.38M+82.1% | $7.56M+76.9% | $6.75M-12.1% | $5.57M-11.3% | $4.06M-46.4% | ||
| $417.63M+178% | $418.46M+160% | $354.7M+205% | $366.29M+207% | $150.26M+20.9% | ||
| $5.54M-21.2% | $5.9M-20.5% | $6.26M-19.7% | $6.64M-18.4% | $7.03M-19.4% | ||
| $23M-16.1% | $24.37M-14.0% | $25.45M-13.2% | $26.49M-16.7% | $27.43M-22.4% | ||
| $25.3M+83.0% | $24.88M+103% | $25.19M+237% | $25.77M+233% | $13.82M+75.1% | ||
| —— | —— | —— | —— | —— | ||
| $472.31M+37.5% | $485.57M+37.1% | $415.46M+16.7% | $426.04M+17.7% | $343.58M-7.5% | ||
| $1.1M-54.3% | $2.57M+14.5% | $2.21M+52.2% | $1.68M+0.1% | $2.41M+42.8% | ||
| $8.73M+62.1% | $12.59M+79.4% | $10.33M+31.7% | $7.26M+25.7% | $5.39M+20.4% | ||
| $10.75M-0.5% | $10.95M+2.2% | $10.91M+160% | $10.9M+158% | $10.81M+166% | ||
| $31.78M+0.9% | $38.3M+19.4% | $37.41M+59.6% | $54.63M+138% | $31.5M+45.4% | ||
| $29.75M-20.3% | $31.76M-18.8% | $33.68M-17.4% | $35.56M-16.2% | $37.35M-14.8% | ||
| $244K-81.0% | $313K-83.4% | $313K-93.7% | $1.55M-68.3% | $1.29M-76.4% | ||
| —— | —— | —— | —— | —— | ||
| $1K— | $1K— | —— | —— | —— | ||
| $1.16B+0.9% | $1.16B+1.3% | $1.15B+1.6% | $1.15B+1.6% | $1.15B+1.7% | ||
| -$864.56M+11.7% | -$859.63M+11.0% | -$920.65M+3.1% | -$924.27M+1.4% | -$979.1M-6.3% | ||
| -$62K— | —— | —— | —— | —— | ||
| $290.59M+75.1% | $296.72M+69.0% | $232.68M+25.3% | $224.85M+16.1% | $165.98M-19.0% | ||
| $472.31M+37.5% | $485.57M+37.1% | $415.46M+16.7% | $426.04M+17.7% | $343.58M-7.5% | ||
| $106.57M+426% | $147.55M+192% | $154.91M+128% | $56.88M+14.4% | $20.24M-56.1% | ||
| $15.58M+1.5% | $45.54M+147% | $18.27M+8.4% | $21.92M+53.3% | $15.35M+4.7% | ||
| —— | —— | —— | —— | —— | ||
| $25.3M+83.0% | $24.88M+103% | $25.19M+237% | $25.77M+233% | $13.82M+75.1% | ||
| $23M-16.1% | $24.37M-14.0% | $25.45M-13.2% | $26.49M-16.7% | $27.43M-22.4% | ||
| —— | —— | —— | —— | —— | ||
| $23M-16.1% | $24.37M-14.0% | $25.45M-13.2% | $26.49M-16.7% | $27.43M-22.4% | ||
| $25.3M+83.0% | $24.88M+103% | $25.19M+237% | $25.77M+233% | $13.82M+75.1% | ||
| $23M-16.1% | $24.37M-14.0% | $25.45M-13.2% | $26.49M-16.7% | $27.43M-22.4% | ||
| $25.3M+83.0% | $24.88M+103% | $25.19M+237% | $25.77M+233% | $13.82M+75.1% | ||
| $8.73M+62.1% | $12.59M+79.4% | $10.33M+31.7% | $7.26M+25.7% | $5.39M+20.4% | ||
| $2.4M-2.5% | $3.37M+219% | $5.84M+576% | $3.78M+92.4% | $2.46M+75.6% | ||
| $2.52M+0.1% | $2.05M-31.3% | $2.7M+95.7% | $2.46M+25.5% | $2.52M+1.8% | ||
| $5.29M— | $5.29M— | $4.07M— | —— | —— | ||
| $8.73M+62.1% | $12.59M+79.4% | $10.33M+31.7% | $7.26M+25.7% | $5.39M+20.4% | ||
| $40.5M-15.9% | $42.7M-14.3% | $44.6M-0.9% | $46.46M-0.4% | $48.16M+0.5% | ||
| $1K— | $1K— | —— | —— | —— | ||
| $32.8M+5.9% | $32.8M+8.1% | $32.21M+8.5% | $31.64M+8.9% | $30.98M+9.0% | ||
| $988K-52.3% | $1.49M-32.9% | $1.34M+10.3% | $1.87M+116% | $2.07M+93.0% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Theravance Biopharma's total assets?
- Theravance Biopharma (TBPH) holds $472.3M in total assets, up 37.5% year over year.
- How much debt does Theravance Biopharma have?
- Theravance Biopharma carries $40.5M in total debt against $290.6M of shareholders' equity, a debt-to-equity ratio of 0.14.
- How much cash does Theravance Biopharma have?
- Theravance Biopharma holds $288.1M in cash and equivalents.
- Can Theravance Biopharma cover its short-term obligations?
- Its current ratio is 13.14 — current assets exceed current liabilities.
- Where does Theravance Biopharma's balance sheet data come from?
- Every line is extracted from Theravance Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
